Simvastatin
Code | Size | Price |
---|
TAR-T0687-10mg | 10mg | £99.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0687-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0687-25mg | 25mg | £113.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0687-50mg | 50mg | £121.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0687-100mg | 100mg | £157.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0687-500mg | 500mg | £295.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Simvastatin is a HMG-CoA Reductase Inhibitor. The mechanism of action of simvastatin is as a Hydroxymethylglutaryl-CoA Reductase Inhibitor.
CAS:
79902-63-9
Formula:
C25H38O5
Molecular Weight:
418.57
Pathway:
Cell Cycle/Checkpoint; Metabolism; Autophagy; Apoptosis
Purity:
0.9995
SMILES:
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
Target:
Apoptosis; Mitophagy; Ferroptosis; HMG-CoA Reductase; Autophagy
References
1. Slater EE, et al. Drugs. 1988, 36 Suppl 3, 72-82.
2. Kureishi Y, et al. Nat Med, 2000, 6(9), 12004-12010.
3. Leung BP, et al. J Immunol, 2003, 170(3), 1524-1530.
4. Kobayashi M, et al. Jpn J Pharmacol, 1989, 49(1), 125-133.
5. Ishida F, et al. Biochim Biophys Acta, 1990, 1042(3), 365-373.
6. Liu Z, et al. Pretreatment Donors after Circulatory Death with Simvastatin Alleviates Liver Ischemia Reperfusion Injury through a KLF2-Dependent Mechanism in Rat. Oxid Med Cell Longev. 2017;2017:3861914.
7. Wei Y H, Liao S L, Wang S H, et al. Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves? Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways[J]. Frontiers in Endocrinology. 2021, 11: 1109.
8. Wei Y H, Liao S L, Wang C C, et al. Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves? Ophthalmopathy through the Regulation of FoxO3a Signaling[J]. Mediators of Inflammation. 2021, 2021.
9. Tang Y, Fang G, Guo F, et al. Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer[J]. Cancer Cell. 2020, 38(1): 115-128. e9.